Topical and systemic treatment use in pediatric patients with AD was increased as compared to the matched control group, including TCS, TCI, PDE4 inhibitors, phototherapy, systemic corticosteroids, immune-suppressive agents, JAK inhibitors, and biological treatments. This evidence concerns the gene PDE4A and Alzheimer disease.